-

Velsera’s 2023 Diagnostics & Discovery Summit: Shaping the Future of Precision Medicine

Inaugural event this week in Boston features key thought leaders and industry visionaries in multi-omics across clinical diagnostics and R&D

BOSTON--(BUSINESS WIRE)--Velsera, a healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to be holding its inaugural Diagnostics & Discovery Summit this week in Boston. The summit’s two-day lineup of notable speakers will highlight advances and areas of collaboration in precision medicine across R&D, clinical diagnostics, healthcare technology, assay development, patient registries and public programs.

Velsera convened this program to showcase the potential power of a connected ecosystem of diverse data, insights and expertise. The summit aims to inspire and engage participants, offering a platform for networking, knowledge exchange and fostering of new ideas. Participants share Velsera’s interest in accelerating target identification, new therapy development, clinical trials optimization and ‘omics-driven diagnostics and decision support at scale.

Featured topics include:

  • AI and machine learning (ML) strategies for precision medicine
  • Bridging the gap between discovery and diagnostics
  • The multi-omic future of precision medicine
  • What universal germline testing means for optimized care
  • The future of biomarker-driven clinical trials

“We are excited to bring together such a distinguished lineup of speakers and thought-provoking panels for this year's summit, as part of our mission to usher in a new era of precision medicine,” said Gavin Nichols, CEO of Velsera. “Attendees can expect a dynamic and stimulating experience, as we explore a wide range of intriguing topics and facilitate meaningful conversations.”

The spotlight session on AI and machine learning will be presented by Meghan M. Dierks, MD, FACS, chief data officer at Komodo Health.

“I am honored to be a part of Velsera’s Diagnostics & Discovery Summit, discussing how AI and machine learning is driving some of the most exciting areas of progress in healthcare,” said Dr. Dierks. “The use of AI and ML in healthcare has accelerated substantially in recent years, particularly in developing highly targeted therapeutics and diagnostics. We are reaching an inflection point, where the impact of AI and ML on direct patient care and our ability to deliver on the promises of precision medicine will be substantial. This is an exciting time to be part of this field, and I look forward to hearing from other industry leaders at the event.”

The summit will take place Tuesday, May 16, and Wednesday, May 17, at the Mandarin Oriental Hotel in Boston. To learn more, visit www.velsera-dds.com, and while registration is closed, you can follow along with the event’s updates and announcements on Velsera’s LinkedIn and Twitter accounts.

About Velsera

Velsera is the precision engine company. Launched in January 2023, we connect healthcare and life sciences to reveal the true promise of precision medicine - a continuous flow of knowledge among researchers, scientists and clinicians around the world, creating insights that radically improve human health. For more information, visit www.velsera.com.

Contacts

Media inquiries
Contact Bill Taggart: bill.taggart@velsera.com, 510.846.2718

Velsera


Release Summary
Velsera is hosting its first Diagnostics & Discovery Summit this week in Boston, convened to shape the future of precision medicine & accelerate R&D
Release Versions

Contacts

Media inquiries
Contact Bill Taggart: bill.taggart@velsera.com, 510.846.2718

Social Media Profiles
More News From Velsera

Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey

LONDON--(BUSINESS WIRE)--Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, have announced a collaboration aimed at advancing cancer diagnostics and treatment in Turkey and nearby regions. This strategic partnership combines Genoks' expertise in genomics with Velsera's innovative Clinical Genomics Workspace (CGW), a cutting-edge platform designed for comprehens...

Genetic Sequence Data Analysis & Reporting Accelerated with Velsera's Release of CGW Plus

BOSTON--(BUSINESS WIRE)--Velsera, a leading global healthcare technology company offering a universal software platform to connect clinical care with discovery, is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform. This update introduces advanced variant quality and clinical evidence review workflows, designed to simplify and accelerate the analysis and reporting of genetic sequence data for clinical laboratory professionals. “With CGW Plus,...

Velsera and Sentieon’s Pangenotyper Wins Bio-IT World 2024 Best-of-Show

BOSTON--(BUSINESS WIRE)--Velsera and Sentieon are pleased to announce their joint receipt of the Best-of-Show award at Bio-IT World 2024 for their innovative NGS secondary analysis solution, Pangenotyper, which improves upon traditional linear genome reference analysis methods by optimizing both accuracy and cost efficiency. Pangenotyper sets a new standard in NGS alignment and variant calling Traditional NGS analysis methods do not take the diversity of human genomes into account, limiting the...
Back to Newsroom